Zimmer Biomet Holdings, Inc. Files 2023 Annual Report on Form 10-K
Ticker: ZBH · Form: 10-K · Filed: Feb 23, 2024 · CIK: 1136869
| Field | Detail |
|---|---|
| Company | Zimmer Biomet Holdings, INC. (ZBH) |
| Form Type | 10-K |
| Filed Date | Feb 23, 2024 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, Annual Report, Zimmer Biomet, Orthopedics, Financials
TL;DR
<b>Zimmer Biomet Holdings, Inc. has filed its 2023 10-K annual report detailing its financial performance and business operations.</b>
AI Summary
ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed a Annual Report (10-K) with the SEC on February 23, 2024. Zimmer Biomet Holdings, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the company's financial performance and business operations for the year 2023. The company's principal executive offices are located at 345 East Main Street, Warsaw, Indiana. Zimmer Biomet Holdings, Inc. was formerly known as Zimmer Holdings Inc., with a name change effective March 15, 2001. The company operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, SIC code 3842.
Why It Matters
For investors and stakeholders tracking ZIMMER BIOMET HOLDINGS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Zimmer Biomet's financial health, operational strategies, and risk factors for the fiscal year 2023, crucial for investors to assess the company's current standing and future prospects. Understanding the details within this report is essential for stakeholders to evaluate the company's compliance with SEC regulations and its position within the competitive orthopedic and surgical supplies market.
Risk Assessment
Risk Level: medium — ZIMMER BIOMET HOLDINGS, INC. shows moderate risk based on this filing. The filing is a standard 10-K, which is a routine annual report. While it contains detailed financial and operational information, it does not inherently signal immediate positive or negative developments beyond the typical disclosures expected in such a filing.
Analyst Insight
Review the detailed financial statements and risk factors within the 10-K to understand Zimmer Biomet's performance and strategic outlook for 2024.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting period)
- 2024-02-23 — Filing Date (Date of submission)
- 10-K — Form Type (Type of filing)
- 001-16407 — SEC File Number (SEC registration number)
- 0000950170-24-019353 — Accession Number (Unique identifier for the filing)
- 148 — Public Document Count (Number of documents in the filing)
Key Players & Entities
- ZIMMER BIOMET HOLDINGS, INC. (company) — Filer name
- ZBH (company) — Ticker symbol
- 2023-12-31 (date) — Fiscal year end
- 2024-02-23 (date) — Filing date
- 345 EAST MAIN STREET, WARSAW, IN 46580 (address) — Business address
- ZIMMER HOLDINGS INC (company) — Former company name
- 2001-03-15 (date) — Date of name change
- 3842 (industry) — Standard Industrial Classification
FAQ
When did ZIMMER BIOMET HOLDINGS, INC. file this 10-K?
ZIMMER BIOMET HOLDINGS, INC. filed this Annual Report (10-K) with the SEC on February 23, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by ZIMMER BIOMET HOLDINGS, INC. (ZBH).
Where can I read the original 10-K filing from ZIMMER BIOMET HOLDINGS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ZIMMER BIOMET HOLDINGS, INC..
What are the key takeaways from ZIMMER BIOMET HOLDINGS, INC.'s 10-K?
ZIMMER BIOMET HOLDINGS, INC. filed this 10-K on February 23, 2024. Key takeaways: Zimmer Biomet Holdings, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The filing covers the company's financial performance and business operations for the year 2023.. The company's principal executive offices are located at 345 East Main Street, Warsaw, Indiana..
Is ZIMMER BIOMET HOLDINGS, INC. a risky investment based on this filing?
Based on this 10-K, ZIMMER BIOMET HOLDINGS, INC. presents a moderate-risk profile. The filing is a standard 10-K, which is a routine annual report. While it contains detailed financial and operational information, it does not inherently signal immediate positive or negative developments beyond the typical disclosures expected in such a filing.
What should investors do after reading ZIMMER BIOMET HOLDINGS, INC.'s 10-K?
Review the detailed financial statements and risk factors within the 10-K to understand Zimmer Biomet's performance and strategic outlook for 2024. The overall sentiment from this filing is neutral.
Key Dates
- 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
- 2024-02-23: Filing Date — Date Zimmer Biomet Holdings, Inc. submitted its 10-K filing.
Filing Stats: 4,333 words · 17 min read · ~14 pages · Grade level 13.5 · Accepted 2024-02-23 16:06:31
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value ZBH New York Stock Exchan
Filing Documents
- zbh-20231231.htm (10-K) — 4998KB
- zbh-ex10_51.htm (EX-10.51) — 25KB
- zbh-ex10_52.htm (EX-10.52) — 32KB
- zbh-ex10_53.htm (EX-10.53) — 42KB
- zbh-ex10_54.htm (EX-10.54) — 157KB
- zbh-ex21.htm (EX-21) — 184KB
- zbh-ex23.htm (EX-23) — 3KB
- zbh-ex31_1.htm (EX-31.1) — 14KB
- zbh-ex31_2.htm (EX-31.2) — 14KB
- zbh-ex32.htm (EX-32) — 7KB
- zbh-ex97_1.htm (EX-97.1) — 30KB
- img60664016_0.jpg (GRAPHIC) — 8KB
- img91265707_0.jpg (GRAPHIC) — 134KB
- 0000950170-24-019353.txt ( ) — 25956KB
- zbh-20231231.xsd (EX-101.SCH) — 2876KB
- zbh-20231231_htm.xml (XML) — 6451KB
Business
Business 4 Item 1A.
Risk Factors
Risk Factors 13 Item 1B. Unresolved Staff Comments 25 Item 1C. Cybersecurity 25 Item 2.
Properties
Properties 26 Item 3.
Legal Proceedings
Legal Proceedings 26 Item 4. Mine Safety Disclosures 26 PART II 27 Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 27 Item 6. [Reserved] 28 Item 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 37 Item 8.
Financial Statements and Supplementary Data
Financial Statements and Supplementary Data 40 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 91 Item 9A.
Controls and Procedures
Controls and Procedures 91 Item 9B. Other Information 92 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 93 PART III 94 Item 10. Directors, Executive Officers and Corporate Governance 94 Item 11.
Executive Compensation
Executive Compensation 94 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 94 Item 13. Certain Relationships and Related Transactions and Director Independence 94 Item 14. Principal Accountant Fees and Services 94 PART IV 95 Item 15. Exhibits and Financial Statement Schedules 95 Item 16. Form 10-K Summary 100 PART I
B usiness
Item 1. B usiness Overview Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic ("CMFT") products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives. In this report, "Zimmer Biomet," "we," "us," "our," "the Company" and similar words refer collectively to Zimmer Biomet Holdings, Inc. and its subsidiaries. "Zimmer Biomet Holdings" refers to the parent company only. Zimmer Biomet Holdings was incorporated in Delaware in 2001. Our history dates to 1927, when Zimmer Manufacturing Company, a predecessor, was founded in Warsaw, Indiana. On August 6, 2001, we were spun off from our former parent and became an independent public company. In 2015, we acquired LVB Acquisition, Inc. ("LVB"), the parent company of Biomet, Inc. ("Biomet"), and LVB and Biomet became our wholly-owned subsidiaries. In connection with the merger, we changed our name from Zimmer Holdings, Inc. to Zimmer Biomet Holdings, Inc. On March 1, 2022, we completed the spinoff of our spine and dental businesses into a new public company, ZimVie Inc. ("ZimVie"). The transaction was intended to benefit our stockholders by enhancing the focus of both Zimmer Biomet and ZimVie to meet the needs of patients and customers and, therefore, achieve faster growth and deliver greater value for all stakeholders. Customers, Sales and Marketing Our primary customers include